Perioperative Durvalumab Plus FLOT Boosts EFS in Resectable Gastric/GEJ Cancer

IMFINZI® (durvalumab) regimen reduced risk of progression, recurrence or death by 29% in early-stage gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial

WILMINGTON, Del.--(BUSINESS WIRE)--Jun 1, 2025-

Perioperative Durvalumab Plus FLOT Boosts EFS in Resectable Gastric/GEJ Cancer

(MedPage Today) -- CHICAGO -- Adding perioperative durvalumab (Imfinzi) to FLOT chemotherapy significantly improved event-free survival (EFS) compared with FLOT alone in patients with resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma...

Durvalumab/FLOT Potential SOC in Resectable Gastric/GEJ Adenocarcinoma

Adding durvalumab to perioperative FLOT upped event-free survival in patients with gastric or gastroesophageal adenocarcinoma eligible for resection.

Durvalumab Plus FLOT Improves EFS in Resectable Gastric/GEJ Adenocarcinoma

Durvalumab plus FLOT improved event-free survival vs placebo in resectable gastric/GEJ cancer.

Durvalumab Regimen Extends EFS in Resectable Gastric/GEJ Adenocarcinoma

Data from the MATTERHORN trial may be “practice-changing” in the management of resectable gastric or gastroesophageal junction adenocarcinoma.

Breakthrough: IMFINZI Immunotherapy Shows 29% Better Survival in Early Gastric Cancer Trial - Key Data Released

First immunotherapy showing 67.4% event-free survival at 2 years in early-stage gastric cancer. Landmark Phase III trial results reveal game-changing outcomes. See full data.